The CancerWeb Report, What's New In Cancer: May, 1996
Lung Cancer

• Paclitaxel for non-small-cell tumors - A treatment program that included paclitaxel (Taxol) with etoposide and radiation gave an 82% objective response rate in non-small-cell lung cancer, with 42% having a partial and 36% a complete response to therapy. This according to investigators at the Sarah Cannon-Minnie Pearl Cancer Center in Nashville, Tennessee. The study has not yet run long enough to get survival figures, but 19 patients (58%) are progression-free at 8 months post treatment. Greco, J Clin Oncol 14:1642, 1996)